O. G. Pybus, M. Charleston, S. Gupta, A. Rambaut, E. C. Holmes et al., The epidemic behavior of the hepatitis C virus, Science, vol.292, p.2323, 2001.

Q. L. Choo, G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley et al., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science, vol.244, pp.359-62, 1989.

D. Lavanchy, Evolving epidemiology of hepatitis C virus, Clin Microbiol Infect, vol.17, pp.107-122, 2011.

M. Thursz and A. Fontanet, HCV transmission in industrialized countries and resource-constrained areas, Nat Rev Gastroenterol Hepatol, vol.11, pp.28-35, 2014.

H. Hagan and E. R. Pouget, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs, J Infect Dis, vol.204, pp.74-83, 2011.

P. K. Nelson, B. M. Mathers, and B. Cowie, Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, Lancet, vol.378, pp.571-83, 2011.

F. El-zanaty and W. A. , Egypt Demographic and Health Survey, July, vol.22, 2008.

C. Frank, M. K. Mohamed, and G. T. Strickland, The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt, Lancet, vol.355, pp.887-91, 2000.

N. Arafa, E. Hoseiny, M. Rekacewicz, and C. , Changing pattern of hepatitis C virus spread in rural areas of Egypt, J Hepatol, vol.43, pp.418-442, 2005.

A. Jimenez, N. Eldin, and F. F. Rimlinger, HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut, vol.59, pp.1554-60, 2010.

J. Pépin, M. Lavoie, and O. G. Pybus, Risk factors for hepatitis C virus transmission in colonial Cameroon, Clin Infect Dis, vol.51, pp.768-76, 2010.

R. Njouom, M. Caron, and G. Besson, Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, Central Africa, PLoS One, vol.7, p.42002, 2012.
URL : https://hal.archives-ouvertes.fr/pasteur-00723648

R. Breban, W. Doss, and G. Esmat, Towards realistic estimates of HCV incidence in Egypt, J Viral Hepat, vol.20, pp.294-96, 2013.

E. Sayed, N. Kandeel, A. Genedy, and M. , Progress toward prevention and control of hepatitis C virus infection-Egypt, MMWR Morb Mortal Wkly Rep, vol.61, pp.545-594, 2001.

H. E. Makhzangy, G. Fagard, and M. Said, Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4, J Med Virol, vol.81, pp.1576-83, 2009.

H. Thein, Y. Q. Dore, G. J. Krahn, and M. D. , Estimation of stagespecifi c fi brosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression, Hepatology, vol.48, pp.418-449, 2008.

F. F. Tanser, T. T. Bärnighausen, E. E. Grapsa, J. J. Zaidi, and M. Newell, High coverage of ART associated with decline in risk of HIV acquisition in rural, Science, vol.339, pp.966-71, 2013.

R. Granich, C. Gilks, C. Dye, D. Cock, K. Williams et al., Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model, Lancet, vol.373, pp.48-57, 2009.

A. Mostafa, S. M. Taylor, and M. El-daly, Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections, Liver Int, vol.30, pp.560-66, 2010.

N. K. Martin, P. Vickerman, and J. Grebely, HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals, Hepatology, vol.58, pp.1598-609, 2013.

A. Munier, D. Marzouk, and F. Abravanel, Frequent transient hepatitis C viremia without seroconversion among healthcare workers in Cairo, PLoS One, vol.8, p.57835, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01402015

L. B. Seeff, Natural history of chronic hepatitis C, Hepatology, vol.36, p.35, 2002.

S. C. Ray, R. R. Arthur, A. Carella, J. Bukh, and D. L. Thomas, Genetic epidemiology of hepatitis C virus throughout Egypt, J Infect Dis, vol.182, pp.698-707, 2000.

S. S. Luby, F. F. Hoodbhoy, A. A. Jan, A. A. Shah, and Y. Y. Hutin, Long-term improvement in unsafe injection practices following community intervention, Int J Infect Dis, vol.9, pp.52-59, 2004.

J. Vos, B. Gumodoka, H. A. Van-asten, Z. A. Berege, W. M. Dolmans et al., Improved injection practices after the introduction of treatment and sterility guidelines in Tanzania, Trop Med Int Health, vol.3, pp.291-96, 1998.

N. K. Martin, P. Vickerman, G. R. Foster, S. J. Hutchinson, D. J. Goldberg et al., Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility, J Hepatol, vol.54, pp.1137-1181, 2011.

N. K. Martin, M. Hickman, S. J. Hutchinson, D. J. Goldberg, and P. Vickerman, Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy, Clin Infect Dis, vol.57, issue.2, pp.39-45, 2013.

K. Roy, G. Hay, R. Andragetti, A. Taylor, D. Goldberg et al., Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature, Epidemiol Infect, vol.129, pp.577-85, 2002.

M. Talaat, S. El-oun, and A. Kandeel, Overview of injection practices in two governorates in Egypt, Trop Med Int Health, vol.8, pp.234-275, 2003.

H. Wedemeyer, Hepatitis C in 2012: on the fast track towards IFN-free therapy for hepatitis C?, Nat Rev Gastroenterol Hepatol, vol.10, pp.76-78, 2013.

R. Anderson and R. May, Infectious diseases of humans: dynamics and control, 1991.

E. J. Aspinall, S. Corson, and J. S. Doyle, Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis, Clin Infect Dis, vol.57, issue.2, pp.80-89, 2013.

. Who, World Health Organization, 2010.

, Guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014.

. Reuters, Gilead off ers Egypt new hepatitis C drug at 99 pct discount, July, vol.22, 2014.